title: Efficacy and tolerability of doxazosin versus enalapril in the treatment of patients with mild-to-moderate hypertension.
abstract: The effects of 4 weeks of treatment with doxazosin or enalapril on diastolic blood pressure (DBP) and plasma lipid levels were studied in 160 patients 18 to 50 years old with mild-to-moderate hypertension. Comparing baseline measurements with measurements taken after 4 weeks, DBP was significantly reduced by 6.8 +/- 7.4 (mean +/- SD) mm Hg and 12.0 +/- 7.1 mm Hg in the doxazosin and enalapril groups, respectively. Systolic blood pressure was significantly decreased from baseline to end of treatment in both groups. There were no significant changes in heart rate from baseline to end of treatment in the doxazosin group, but there was a statistically significant decrease in heart rate in the enalapril group. High-density lipoprotein cholesterol increased statistically significantly in the doxazosin group but not in the enalapril group. A decrease in triglycerides was statistically significant with respect to the doxazosin group and was close to significance for the enalapril group. Forty-nine (62%) patients in the doxazosin group and 43 (54%) patients in the enalapril group reported at least one adverse event. Significant reductions in DBP after 4 weeks of treatment were achieved by both drugs, each taken once daily. This reduction was more pronounced in the enalapril group 24 hours postdose, with a mean final daily dose of 2.8 mg of doxazosin and 12.6 mg of enalapril. However, even relatively short-term treatment with low-dose doxazosin showed a more favorable effect on lipids than did enalapril.
authors.affiliation: Astra Pharma Inc., Mississauga, Ontario, Canada.
authors.forename: K W
authors.initials: KW
authors.lastname: Tan
authors.forename: S A
authors.initials: SA
authors.lastname: Frise
mesh_terms: D000293:Adolescent; D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D004311:Double-Blind Method; D017292:Doxazosin / Q000009:adverse effects / Q000627:therapeutic use*; D004656:Enalapril / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged
chemical_list: D000317:Adrenergic alpha-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D008055:Lipids; D004656:Enalapril; D017292:Doxazosin